ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
NYSE Content Advisory: Pre-Market update + CEO survey reveals growth as top priority
NEW YORK, May 28, 2025 /PRNewswire/ -- The New York Stock Exchange…
